IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia

European Journal of Haematology

Volumn 84, Issue 2, 2010, Pages 109-116

  Mansouri, Mahmoud R ^a   Sevov, Marie ^a   Åleskog, Anna ^b   Jondal, Mikael ^c   Merup, Mats ^d   Sundström, Christer ^a   Osorio, Lyda ^c   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic lymphocytic leukemia; IGHV gene mutational status; IGHV3 21 gene usage; Prognosis; TCL1 expression

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; MUTANT PROTEIN; REGULATOR PROTEIN; T CELL LEUKEMIA LYMPHOMA PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE;

EID: 74049137481     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01369.x     Document Type: Article

References (28)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 94 : 1840 1847.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 94 : 1848 1854.
3. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, Dohner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002 100 : 1410 1416. (Pubitemid 34864299)
4. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002 100 : 1177 1184.
5. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003 101 : 4952 4957.
6. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006 107 : 2889 2894.
7. Ghia EM, Jain S, Widhopf GF II., et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008 111 : 5101 5108.
8. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005 105 : 1678 1685.
9. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007 109 : 259 270.
10. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, Russo G. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994 91 : 12530 12534.
11. Virgilio L, Isobe M, Narducci MG, Carotenuto P, Camerini B, Kurosawa N, Abbas ar R, Croce CM, Russo G. Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad Sci USA 1993 90 : 9275 9279.
12. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000 6 : 395 407.
13. Herling M, Patel KA, Hsi ED, Chang KC, Rassidakis GZ, Ford R, Jones D. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol 2007 31 : 1123 1129.
14. Roos J, Hennig I, Schwaller J, et al. Expression of TCL1 in hematologic disorders. Pathobiology 2001 69 : 59 66.
15. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones D. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006 20 : 280 285.
16. Browning RL, Geyer SM, Johnson AJ, et al. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007 31 : 1737 1740.
17. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009 Epub ahead of print XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006 103 : 11713 11718.
18. Aggarwal M, Villuendas R, Gomez G, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol 2009 22 : 206 215.
19. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC : Lyon, 2008.
20. Li AH, Rosenquist R, Forestier E, Holmberg D, Lindh J, Lofvenberg E, Roos G. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol 1999 63 : 211 218.
21. Giudicelli V, Chaume D, Lefranc MP. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004 32 (Web Server issue) : W435 40.
22. Lefranc MP, Giudicelli V, Kaas Q, Duprat E, Jabado-Michaloud J, Scaviner D, Ginestoux C, Clement O, Chaume D, Lefranc G. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2005 33 (Database issue) : D593 7.
23. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 1916. (Pubitemid 32064784)
24. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006 66 : 11590 11593.
25. Cardinaud B, Moreilhon C, Marcet B, Robbe-Sermesant K, Lebrigand K, Mari B, Eclache V, Cymbalista F, Raynaud S, Barbry P. miR-34b/miR-34c: a regulator of TCL1 expression in 11q-chronic lymphocytic leukaemia? Leukemia 2009 23 : 2174 2177.
26. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008 105 : 19643 19648.
27. Despouy G, Joiner M, Le Toriellec E, Weil R, Stern MH. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. Blood 2007 110 : 4406 4416.
28. Shen RR, Ferguson DO, Renard M, Hoyer KK, Kim U, Hao X, Alt FW, Roeder RG, Morse HC III., Teitell MA. Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood 2006 108 : 1991 1998.